The Reporting Items for Patent Landscapes statement

Nat Biotechnol. 2018 Nov 9;36(11):1043-1047. doi: 10.1038/nbt.4291.

James A Smith^{1

2}, Zeeshaan Arshad^{2

3}, Anthony Trippe⁴, Gary S Collins^{1

5}, David A Brindley^{2

6

7

8

9}, Andrew J Carr^{1

5}

¹ Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
² The Oxford-UCL Centre for the Advancement of Sustainable Medical Innovation (CASMI), University of Oxford, Oxford, UK.
³ School of Medicine, University of Cambridge, Cambridge, UK.
⁴ Patinformatics LLC, Dublin, Ohio, USA.
⁵ NIHR Oxford Biomedical Research Centre, John Radcliffe Hospital, Oxford, UK.
⁶ Department of Paediatrics, University of Oxford, Children's Hospital, John Radcliffe, Oxford, UK.
⁷ Centre for Behavioural Medicine, UCL School of Pharmacy, University College London, London, UK.
⁸ Harvard Stem Cell Institute, Cambridge, Massachusetts, USA.
⁹ USCF-Stanford Center of Excellence in Regulatory Science and Innovation (CERSI), San Francisco, California, USA.

Abstract

The reporting quality of patent landscapes is inadequate. The Reporting Items for Patent Landscapes (RIPL) checklist can improve reporting quality.